Recent advances predict a bright future for nebulizers

Abstract

Purpose of reviewWith the improvement in device technology and delivery methods of inhaled medications, along with development of novel compounds and recognition of the importance of personalized approach in the management of chronic airway diseases, nebulizers have not only maintained their place in the treatment hierarchy of airway disease but have also proven a vital platform for the development of new classes of drugs. Recent findingsThis short review explores recent advances in nebulized drug delivery in chronic obstructive pulmonary disease and other chronic airway diseases, emphasizing the progress in nebulizer technology, physiologic advantages of nebulized drug delivery and the high versatility of currently available and developing nebulizer-delivered pharmacotherapies. SummaryVersatility and efficiency of nebulizers allows for a broad spectrum of existing and novel therapies to be clinically studied, facilitating the progress in phenotype-targeted pharmacotherapies in the management of chronic airway diseases Keywords aerosolized drugs, chronic airway disease, chronic obstructive pulmonary disease, nebulizer, novel pharmacotherapies, phenotype && ,8,9]. Here, we discuss recent advances in nebulized drug delivery in COPD and other airway diseases with an emphasis on the advantages of nebulizer-delivered approaches compared with hand-held inhalers.

The value of direct determination of peak inspiratory flow for choosing the optimal inhaler in patients with bronchial asthma

“…Наименьшее количество больных с сПИП отмечено при использовании ингаляторов с нулевым сопротивлением -9,1%. Это позволяет считать оправданным при обострении болезни предпочтительное применение у всех пациентов небулайзера с принудительной подачей лекарства в дыхательные пути, ДАИ со спейсером или респимата (R0) без предварительного определения ПИП [4].…”

Reply to Gan et al., to Calzetta et al., and to Poor

“…Approximately 45% of patients with COPD have a nebulizer therapy, and nearly 70% use their nebulizer on a regular basis ( 13 ). Development of several long-acting bronchodilators and multiple additional concomitant therapies used in COPD ( 14 ), which are delivered exclusively via nebulizer, provides additional evidence of the suitability of ensifentrine formulation in care of individuals with COPD.…”